



hydrOCHLOROTHIAZIDE

Indication	<ul style="list-style-type: none"> Fluid overload¹ Adjunct therapy to diazoxide for prevention of fluid retention 	
ORAL	Presentation <ul style="list-style-type: none"> Oral solution: 5 mg in 1 mL <ul style="list-style-type: none"> Available from QH Central Pharmacy 	
	Dosage¹ <ul style="list-style-type: none"> 1–2 mg/kg every 12 hours 	
	Preparation <ul style="list-style-type: none"> Nil preparation required 	
	Administration <ul style="list-style-type: none"> Draw up prescribed dose Oral/OGT/NGT with feeds 	
ORAL	Presentation <ul style="list-style-type: none"> Tablet: 25 mg (if no oral solution available) 	
	Dosage¹ <ul style="list-style-type: none"> 1–2 mg/kg every 12 hours 	
	Preparation <ul style="list-style-type: none"> Disperse tablet in 10 mL of water for injection and allow tablet to dissolve (takes about 1 minute) Agitate gently if required <ul style="list-style-type: none"> Concentration now equal to 2.5 mg/mL 	
	Administration <ul style="list-style-type: none"> Draw up prescribed dose Oral/OGT/NGT with feeds 	
Contraindication	<ul style="list-style-type: none"> Contraindication <ul style="list-style-type: none"> Nil known 	
Caution	<ul style="list-style-type: none"> Caution <ul style="list-style-type: none"> If significant hepatic or renal impairment¹, seek specialist advice Hypokalaemia¹, hyperuricaemia¹, impaired cardiac circulation², significant jaundice (displaces bilirubin from albumin)³ 	
Special considerations	<ul style="list-style-type: none"> Refer to Queensland Clinical Guideline: Hypoglycaemia-newborn⁴ 	
Monitoring	<ul style="list-style-type: none"> Electrolytes^{1,5}, serum urea¹, BGL¹ Urine output¹ BP^{1,5} 	
Compatibility	<ul style="list-style-type: none"> Nil known 	
Incompatibility	<ul style="list-style-type: none"> Nil known 	
Interactions	<ul style="list-style-type: none"> Diazoxide: increased risk of hyperglycaemia and hypotension⁶ Digoxin: increased risk of digoxin toxicity (vomiting, arrhythmias)⁶ Fluconazole, voriconazole: increased risk of hypokalaemia and cardiac arrhythmias⁶ Hydrocortisone: increased risk of hypokalaemia and cardiac arrhythmias⁶ NSAIDs: decreased effectiveness of hydrochlorothiazide and increased risk of nephrotoxicity^{6,7} 	
Stability	<ul style="list-style-type: none"> Oral solution <ul style="list-style-type: none"> Store at 2–8 °C. Discard 30 days after opening or as per local policy Tablet <ul style="list-style-type: none"> Store below 25° C⁸ Use dispersed solution immediately 	
Side effects	<ul style="list-style-type: none"> Blood pathology: electrolyte disturbances¹ (e.g. hypokalaemia¹, hyponatraemia¹, hyperuricaemia¹, hypochloaemic alkalosis², hypomagnesaemia², hypercalcaemia²), hyperglycaemia¹, agranulocytosis², leucopenia², thrombocytopenia² Digestive: pancreatitis (rare)² 	
Actions	<ul style="list-style-type: none"> Diuretic and hypotensive agent affecting the renal tubular mechanism of electrolyte reabsorption^{1,2} 	
Abbreviations	BGL: blood glucose level, BP: blood pressure, OGT: orogastric tube, NGT: nasogastric tube, NSAIDs: non-steroidal anti-inflammatory drugs	

Keywords

diuretic, heart failure, hydrochlorothiazide, neonatal medicine, neonatal monograph, fluid overload, fluid retention, diazoxide

The Queensland Clinical Guideline [Neonatal medicines](#)⁹ is integral to and should be read in conjunction with this monograph. Refer to the disclaimer. Destroy all printed copies of this monograph after use.

References

1. Merative™ Micromedex®. Hydrochlorothiazide. In: NeoFax®/Pediatrics (electronic version). Ann Arbor, Michigan, USA 2025 [cited 2025 May 13]. Available from: <https://www.micromedexsolutions.com>.
2. Australian Medicines Handbook. Hydrochlorothiazide. [Internet]. Adelaide: Australian Medicines Handbook Pty Ltd; January 2025 [cited 2025 May 13]. Available from: <http://www.amhonline.amh.net.au>.
3. Wennberg RP, Rasmussen LF, Ahlfors CE. Displacement of bilirubin from human albumin by three diuretics. *The Journal of Pediatrics* 1977;90(4):647-50. doi:10.1016/S0022-3476(77)80393-4.
4. Queensland Clinical Guidelines. Hypoglycaemia-newborn. Guideline No. MN23.8-V13-R28. [Internet]. Queensland Health. 2023. [cited 2025 May 13]. Available from: <https://www.health.qld.gov.au/qcg>.
5. Australian Medicines Handbook Children's Dosing Companion. Hydrochlorothiazide. [Internet]. Adelaide: Australian Medicines Handbook Pty Ltd; January 2025 [cited 2025 May 13]. Available from: <http://www.amhonline.amh.net.au>.
6. British National Formulary for Children (BNFC) online. Hydrochlorothiazide. [Internet]: Royal Pharmaceutical Society; 2025 [cited 2025 May 20]. Available from: <https://www.medicinescomplete.com>.
7. MIMS Online. Hydrochlorothiazide (Dithiazide). [Internet]: MIMS Australia; September 2017 [cited 2025 May 13]. Available from: <https://www.mimsonline.com.au>.
8. Therapeutic Goods Administration (TGA). Hydrochlorothiazide (Dithiazide 25 mg tablets). [Internet]. Canberra: Australian Government; 2022 [cited 2025 May 13]. Available from: <http://www.tga.gov.au>.
9. Queensland Clinical Guidelines. Neonatal medicines. Guideline No. MN19.54-V1-R24. [Internet]. Queensland Health. 2019. [cited 2025 April 29]. Available from: <https://www.health.qld.gov.au/qcg>.

Document history

ID number	Effective	Review	Summary of updates
NMedQ19.022-V1-R24	25/08/2019	25/08/2024	Endorsed by Queensland Neonatal Services Advisory Group (QNSAG)
NMedQ25.022-V2-R30	18/07/2025	18/07/2030	Full review. Endorsed by QNSAG <ul style="list-style-type: none"> • No change to dose or frequency • Added: caution if significant hepatic or renal impairment • Updated: indication, interactions, stability, side effects, actions

QR code